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Abstract
Background: In Germany, risk of hepatitis C virus (HCV) infection is highest among people who inject drugs
(PWID). New injectors (NI) are particularly vulnerable for HCV-acquisition, but little is known about health seeking
behaviour and opportunities for intervention in this group. We describe characteristics, HCV prevalence, estimated
HCV incidence and awareness of HCV-status among NIs and missed opportunities for hepatitis C testing.
Methods: People who had injected drugs in the last 12 months were recruited into a cross-sectional
serobehavioural study using respondent-driven sampling in 8 German cities, 2011–2014. Data on sociodemographic
characteristics, previous HCV testing and access to care were collected through questionnaire-based interviews.
Capillary blood was tested for HCV. People injecting drugs < 5 years were considered NI.
Results: Of 2059 participants with available information on duration of injection drug use, 232 (11% were NI.
Estimated HCV incidence among NI was 19.6 infections/100 person years at risk (95% CI 16–24). Thirty-six percent of
NI were HCV-positive (thereof 76% with detectable RNA) and 41% of those HCV-positive were unaware of their
HCV-status. Overall, 27% of NI reported never having been HCV-tested. Of NI with available information, more than
80% had attended low-threshold drug services in the last 30 days, 24% were released from prison in the last 12
months and medical care was most commonly accessed in hospitals, opioid substitution therapy (OST)-practices,
practices without OST and prison hospitals.
Conclusion: We found high HCV-positivity and low HCV-status awareness among NI, often with missed
opportunities for HCV-testing. To increase early diagnosis and facilitate treatment, HCV-testing should be offered in
all facilities, where NI can be reached, especially low-threshold drug services and addiction therapy, but also prisons,
hospitals and practices without OST.
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Background
Chronic hepatitis C virus (HCV) infection can lead to
liver cirrhosis, liver failure and hepatocellular carcinoma.
Currently, no effective vaccine exists but infections can
be cured with antiviral treatment. The WHO aims at
eliminating viral hepatitis as a public health threat by
2030 [1] and Germany has committed to this elimination
agenda. A joint strategy for HIV, hepatitis B/C and other
sexually transmitted infections was published by the
German Ministry of Health in 2016 [2]. Major obstacles
to overcome include a high proportion of people who
are not aware of their infection and, linkage to care [3].
Germany is a low prevalence country for HCV infection.
In a population-based survey of the general adult popula-
tion living in Germany conducted in 2008–2011, HCV-
antibody prevalence was 0.3% and HCV-RNA prevalence
0.2% [4]. People who inject drugs (PWID) are underrepre-
sented in this survey and account for nearly 80% of newly
diagnosed HCV infections notified in Germany with infor-
mation on the mode of transmission [5].
Several studies have found HCV incidence to be high-
est in the first years of injection drug use (IDU) [6, 7],
but little is known about the health seeking behaviour
and opportunities for intervention in people who re-
cently began injecting drugs, which in the following are
referred to as “new injectors” (NI). Therefore, we ana-
lysed data from a cross-sectional study among PWID in
Germany to describe HCV prevalence, estimated inci-
dence and missed opportunities for HCV-testing and
promotion of prevention measures in this group, with a
focus on settings that could be used to reach NI in
Germany and similar countries.
Methods
We analysed data from the DRUCK-study, a cross-
sectional study conducted between 2011 and 2014 using
respondent-driven sampling to recruit PWID that had
injected drugs in the last 12 months in one of eight Ger-
man cities (Berlin, Essen, Leipzig, Munich, Frankfurt,
Hanover, Hamburg, Cologne). Data on sociodemo-
graphic characteristics, previous HCV testing and access
to care were collected through questionnaire-based face-
to-face interviews. Capillary blood was tested for HCV
antibodies and RNA. More detailed methods and the full
study protocol have been published elsewhere [8, 9]. To
capture all participants who had been exposed to HCV,
we defined participants with detectable HCV antibody
and/or HCV-RNA as HCV-positive for this analysis.
We defined NI as people injecting drugs for less than
5 years and long-term injectors (LI) as people injecting
drugs for 5 years or longer.
Stata version 15.1 was used to carry out statistical ana-
lyses. X2-tests were performed and odds ratios using
univariable logistic regression were calculated to com-
pare groups.
Assuming that all participants were HCV-negative
before they began injecting drugs, we estimated HCV
incidence among NI as follows: date of study partici-
pation, month and year of birth and age when IDU
was initiated was collected. Using stochastic simula-
tion and assuming uniform distribution, we simulated
the (unknown) month injection drug use was initiated
and the (unknown) later time point HCV infection
occurred based on 200 realisations in each case. For
each realisation, we performed a bootstrap to account
for the sampling error and characterised the resulting
probability distribution by its mean and the 2.5 and
97.5 percentiles.
Results
Of 2077 participants that provided a blood sample, in-
formation on duration of IDU was available for 2059 of
whom 232 (11%) were NI (range 8.1% in Cologne
(former West Germany) - 19.8% in Leipzig (former East
Germany)).
Of NI, 31% were female, 27% were first-generation mi-
grants and 22% reported being homeless (defined as
reporting living on the streets or in homeless shelters as
main residence in the last 12 months).
Compared to LI, NI were significantly older at the
time of initiation of IDU, were significantly less likely to
have injected cocaine and significantly more likely to
have injected methamphetamines (mainly in Leipzig) in
the last 30 days. We did not find any significant differ-
ences in unsafe drug injecting behaviour in the last 30
days between LI and NI.
In study cities with syringe vending machines, NI were
significantly more likely than LI to have used them to
obtain sterile injecting equipment in the last 30 days
(53% vs 38%, p = 0.006) and to mention them as their
main source of sterile syringes and needles (28% vs 16%,
p = 0.004).
For a detailed comparison of NI and LI see Table 1.
HCV-status, history of HCV-testing and awareness of HCV
positivity
Of 2077 participating PWID, 66% (n = 1361) were HCV-
positive: 22% (n = 457) were anti-HCV-positive and RNA-
negative, 41% (n = 857) anti-HCV and RNA-positive, 2.3%
(n = 47) anti-HCV-negative and RNA-positive. Prevalence
of HCV-antibody and/or RNA positivity was 36% in NI
and increased with duration of IDU, reaching 72% in par-
ticipants injecting drugs for 10 years or longer. NI were
less likely to be HCV-positive (36% vs 70%, p < 0.0001),
but among HCV-positives, a higher proportion of NI had
detectable HCV-RNA (76% vs 66%, p = 0.06); while pro-
portions of NI and LI with chronic infection (anti-HCV-
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Table 1 Sociodemographic characteristics, drug injection behaviour and HCV-status, awareness and testing experience of PWID
participating in the German DRUCK-study 2011–2014 by duration of injection drug use
Injecting drugs < 5 years (N = 232) Injecting drugs ≥ 5 years (N = 1827) p
n Proportionk (%) n Proportionk (%)
Sociodemographic characteristics
Female 73 31.5 403 22.1 0.001**
Age ≤ 25 years 71 30.6 62 3.4 < 0.001***
2nd-generation migranta 26 11.2 273 14.9 0.128
1st-generation migrantb 63 27.2 393 21.5 0.051
Did not graduate from school 46 19.8 250 13.7 0.012*
A-level 23 9.9 182 10.0 0.982
Main place of residence in the last 12 months (max 2 entries)
Own flat 111 48.1 1040 57.5 0.006**
With family or friends 57 24.7 297 16.4 0.002**
Homeless, staying in shelters 50 21.7 258 14.3 0.003**
Ever homelessc 132 57.1 1226 67.3 0.002**
Ever in prison 143 61.9 1518 83.3 < 0.001***
Released from prison in the last 12 monthsd 37 24.3 332 24.2 0.965
Sources of income in the last 12 months
Job (including unemployment benefit I) 61 26.4 384 21.2 0.069
State benefits 171 74.0 1548 85.3 < 0.001***
Selling newspapers, begging, dealing 110 47.6 673 37.1 0.002**
Sex work 17 7.4 60 3.3 0.002**
Injection behavior
Age at first injection < 18 years 19 8.2 623 34.1 < 0.001***
Injecting daily in the last 30 days 63 34.2 452 30.1 0.244
Substance injected in the last 30 daysf
Heroin 130 56.0 1109 60.8 0.165
Cocaine 73 31.5 752 41.2 0.004**
Crack 10 4.3 98 5.4 0.504
Speed (amphetamines) 11 4.7 60 3.3 0.254
Crystal (metamphetamines) g 17 7.4 64 3.5 0.005**
Substance consumed in the last 30 days
Heroin 180 77.6 1355 74.3 0.217
Cocaine 95 41.0 908 49.8 0.011*
Crack 54 23.4 461 25.3 0.534
Speed (amphetamines) 49 21.1 234 12.8 0.001**
Crystal (metamphetamines)g 23 10.0 97 5.3 0.005**
Most common setting of drug injection in the last 30 daysh
Alone at homee 76 42.2 678 45.4 0.425
In consumption roome,i 24 27.6 195 31.9 0421
With good acquaintancese 75 41.2 484 32.4 0.017*
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positive, detectable RNA) were comparable (58% vs 63%,
p = 0.31), the proportions of recent infections (anti-HCV-
negative, detectable RNA) were significantly higher in NI
(18.1% vs 2.4%, p < 0.0001).
HCV positivity among NI was lowest in Leipzig and
Munich (both 20%) and highest in Hamburg (58%).
Estimated HCV incidence among NI was 19.6 infec-
tions/100 person years at risk (95% CI 16–24); if only
participants injecting less than 2 years were considered,
estimated incidence was 36.4 infections/100 person years
at risk (95% CI 21–56).
NI were less likely to ever have been tested for
HCV (73% vs 94%, p < 0.0001) and if HCV positive,
more likely to be unaware of their HCV status (41%
vs 13%, p < 0.0001). Reported testing experience
among NI was lowest in Leipzig (38%) and in the
other study cities ranged between 67% (Cologne) and
89% (Hamburg).
Table 1 Sociodemographic characteristics, drug injection behaviour and HCV-status, awareness and testing experience of PWID
participating in the German DRUCK-study 2011–2014 by duration of injection drug use (Continued)
Injecting drugs < 5 years (N = 232) Injecting drugs ≥ 5 years (N = 1827) p
n Proportionk (%) n Proportionk (%)
With steady partnere 24 13.3 241 16.1 0.317
With hardly known or unknown peoplee 15 8.3 125 8.4 0.984
Unsafe use in the last 30 dayh
Used used needles or syringes 19 10.4 133 8.8 0.482
Used water from a shared container 45 24.7 316 21.4 0.302
Used used spoons or filters 40 22.1 280 18.7 0.268
Source for sterile needles and syringes in the last 30 daysh
Low threshold services 115 62.2 1069 70.2 0.025*
Syringe vending machinej 48 52.8 290 37.9 0.006**
Pharmacy (bought) 67 38.2 656 44.1 0.142
Access to addiction therapy
Ever in detoxification 143 61.6 1517 83.2 < 0.001***
Ever in weaning/rehabilitation program 80 34.5 1004 55.1 < 0.001***
Ever in outpatient substitution therapy 126 54.3 1532 84.0 < 0.001***
Currently in outpatient substitution therapy 68 29.3 945 51.8 < 0.001***
HCV status, awareness and testing experience
HCV positive 83 35.8 1270 69.5 < 0.001***
Detectable HCV-RNA 63 27.2 836 45.8 < 0.001***
Of HCV positive: Unaware of HCV positive status 33 40.7 157 12.6 < 0.001***
Ever tested for HCV 153 73.2 1653 93.6 < 0.001***
Report negative HCV test, last test > 12 months ago 32 36.8 135 38.8 0.730
aBorn in Germany, mother and/or father born abroad
bBorn outside of Germany
cDefined as reporting living on the streets or in homeless shelters as main residence in the last 12months
dNot asked in Berlin, Essen
eLast 30 days
fSubstance consumed in last 30 days and most common mode of consumption injection
gMethamphethamine use was concentrated in Leipzig (East Germany) and to a lower extent in Munich (South Germany), while it played almost no role in other
study cities
hOnly answered if participants injected drugs in the last 30 days
iInformation available for Essen, Berlin, Hamburg; reported use of drug consumption rooms varied widely between cities: highest use in Hamburg (> 60% reported
by NI and LI), lowest use in Berlin (< 10% reported by NI and LI)
jExist in Berlin, Essen, Cologne, Munich
kof responding participants
*p < 0.05
**p < 0.01
***p < 0.001
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Uptake of medical care and addiction services: access
points used by NI
In order to identify ways to reach NI, this part of the
analysis focuses on NI.
Medical care was accessed by 82% of NI (n = 192)
within the last 12 months. Most commonly mentioned
last access points were practices without addiction ser-
vices (31%, 58/186), practices offering opioid substitu-
tion therapy (OST, 30%, 55/186), hospitals (27%, 50/186)
and prison hospitals (6.5%, 12/186).
Release from prison in the last 12 months was reported
by 24% (37/152 with information, not asked in 2 study
cities).
At the time of study, 75% of NI had already received
at least one form of addiction therapy: 62% had ever re-
ceived inpatient detoxification, 54% OST, thereof 29%
currently and 34% had ever received long-term addiction
therapy (93% as inpatient).
Information on last visit to low threshold drug services
was collected in 5 study cities; in those 83% (105/127)
reported attendance in the last 30 days.
Previous HCV testing among NI
Of NI that reported previous HCV-testing, 85% (130/
153) provided details on the place where this was per-
formed; the five most commonly mentioned places were
practices providing OST (35%, 45/130), hospitals (33%,
43/130), practices without addiction services (14%, 18/
130), low threshold drug services (8.5%, 11/130) and
prisons (8.5%, 11/130).
Of 56 NI (27%) that reported never having been tested
for HCV, 29% (n = 16) were HCV-positive. Previous ac-
cess to addiction services was reported by 57%: 46% had
been in inpatient detoxification, 27% in long-term addic-
tion therapy programs and 27% in outpatient OST,
thereof 18% currently (see Table 2). At least 21 NI with-
out self-reported HCV testing experience had attended
low-threshold drug services in the last 30 days (75%, 21/
28 with information).
In the preceding 12 months, 24% (10/41 with informa-
tion) were released from prison and 79% had sought
medical care; most commonly mentioned points of con-
tact were hospitals (40%) and practices without addiction
services (37%).
Reported HCV testing experience was higher in fe-
males (78% vs 71%, p = 0.33), first-generation migrants
(29% vs 21%, p = 0.25) and NI living in their own accom-
modation (52% vs 41%, p = 0.16); however, differences
were not statistically significant (Table 2).
Significantly lower testing experience was reported
from NI younger than 25 years (OR in univariable ana-
lysis 2.2, 95% CI 1.2–4.2) and those injecting amphet-
amines or methamphetamines (OR in univariable
analysis 4.3, 95% CI 1.8–10.1).
Although low threshold drug services were the most
commonly reported source of sterile needles and syrin-
ges, NI that denied previous HCV testing were signifi-
cantly less likely to report them as source (46% vs 67%,
p = 0.01) and were more likely than NI with testing
experience to obtain their syringes and needles from syr-
inge vending machines (36% vs 25%, p = 0.3) and phar-
macies (26% vs 18%, p = 0.2) (Table 2).
NI without OST experience were less likely to ever
have undergone HCV testing (56% vs 87%, p < 0.0001).
They had a shorter duration of IDU (median 2 vs 3
years, p = 0.02), a lower HCV prevalence (27% vs 43%
with OST, p = 0.014) and most commonly accessed med-
ical care in practices without OST (51%), hospitals (26%)
and prisons (10%).
HCV-positive NI that last accessed medical care in
hospitals were more likely to be unaware of their HCV
infection than those that last accessed care in OST-
practices (OR 9.9, 95% CI 2.2–43).
Discussion
We found high HCV positivity and low awareness of
HCV-positive status among participating NI. Among NI-
estimated HCV incidence was 19.6/100 person years at
risk, comparable to the estimated incidence among NI in
New York 2000/2001 and slightly lower than in Catalonia
2010/2011 (18 and 25/100 person years at risk, respect-
ively; both using a similar definition of NI, [10, 11]). Esti-
mated HCV incidence was higher in study participants
with IDU below 2 years (36/100 person years at risk), sup-
porting that HCV infection often occurs early after initi-
ation of IDU.
HCV prevalence was more than 100-times higher in
NI than in a representative study of the “general adult
population in Germany” and more than 220-times in LI
[4]. Given that seroprevalence increases with time of
IDU, it is especially important to reach NI with preven-
tion measures and early HCV-testing.
Studies suggest that awareness of HCV positivity is asso-
ciated with sustained protective behavioural changes, for
example reducing injection risk behaviour [12, 13]. Aware-
ness is a prerequisite for being linked into care and receiv-
ing antiviral treatment. Additionally it provides an
opportunity for counselling around safer injection prac-
tices and linkage to effective prevention measures like
OST, needle exchange and other harm reduction services.
In our study, more than 40% of HCV-positive NI were
unaware of their HCV status, often with missed oppor-
tunities for HCV testing.
More than 50% of NI that reported never having been
tested for HCV had previously been in contact with addic-
tion therapy, many in an inpatient setting or in the form
of OST, which involves regular engagement with services.
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Table 2 HCV-status, awareness, injection behaviour and access to addiction and medical care of new injectors by self-reported HCV-
testing experience prior to study
Reported previous HCV-test (N = 153) Reported no previous HCV-test (N= 56) p
n %i n %i
Sociodemographic characteristic
Female 49 32.0 14 25.0 0.327
Age 25 years 39 25.5 24 42.9 0.015*
1st-generation migranta 45 29.4 12 21.4 0.251
2nd-generation migrantb 13 8.5 6 10.7 0.621
Mainly homeless, staying in sheltersc 31 20.4 17 30.4 0.130
Ever in prison 94 61.8 36 64.3 0.747
Released from prison in the last 12 monthsd 22 23.2 10 24.4 0.876
HCV status
HCV-positive 64 41.8 16 28.6 0.081
Detectable HCV-RNA 47 30.7 14 25.0 0.421
Of HCV-positive: unaware of HCV-positive status 14 22.6 16 100.0 < 0.001***
Access to addiction therapy
Drug addiction ever treated 128 83.7 32 57.1 < 0.001***
Ever in detoxification 105 68.6 26 46.4 0.008**
Ever in weaning/rehabilitation program 60 39.2 15 26.8 0.097
Ever in outpatient substitution 101 66.0 15 26.8 < 0.001***
Currently in outpatient substitution 52 34.0 10 17.9 0.024*
Sought medical care within the last 12 months 127 83.0 44 78.6 0.462
If accessed medical care within 12 months: last access point
Hospital 25 20.2 17 39.5 0.012*
Practice without addiction services 37 29.8 16 37.2 0.371
Practice with OST 44 35.5 6 14.0 0.008**
Detention facilities (prison hospital) 11 8.9 1 2.3 0.152
Low threshold drug services 4 3.2 1 2.3 0.765
Rehabilitation 2 1.6 1 2.3 0.762
Local public health office 1 0.8 1 2.3 0.430
Main source for sterile needles and syringes in the last 30 days
Low threshold services 80 67 21 46 0.011*
Bought in pharmacies 21 18 12 26 0.224
Syringe vending machinee 16 25 8 36 0.325
Visited low threshold drug services in the last 30 daysf 77 88 21 75 0.112
Drug injection behaviour in the last 30 daysg
Injected drugs 126 82.4 47 83.9 0.789
Daily injection 46 36.8 13 27.7 0.260
Injection of heroin 93 60.8 26 46.4 0.063
Injection of cocaine 55 36.0 13 23.1 0.082
Injection of crack 8 5.3 2 3.6 0.613
Injection of amphetamines 7 4.6 4 7.1 0.462
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Engagement in addiction therapy is an important oppor-
tunity for HCV testing that should not be missed.
As could be shown in other studies, we found that NI
engaged in OST were more likely to have been tested
for HCV than those not receiving OST [14]. However,
focusing on OST facilities, does exclude non-opioid
dependent PWID and NI that are not (yet) linked to
these services.
NI in our study often accessed medical care in hospitals
or primary care without focus on addiction care and OST.
In the context of acute medical presentation in hospi-
tals, HCV screening and discussion of test results are chal-
lenging. Although an American pilot study showed that
emergency room-based HCV testing focused on PWID
could be successfully integrated into clinical practice, find-
ing a high prevalence of HCV, the study also encountered
significant challenges linking those found to be HCV-
positive to care [15]. Nevertheless, testing in emergency
departments could at least help improve the level of
awareness of one’s HCV-status, a first step in the cascade
of care. Opt-out testing for blood borne viruses including
HCV reduces barriers and stigma around testing; in sev-
eral emergency department-based studies, it was feasible
and identified unknown HCV-infections [16, 17]. How-
ever, implementing routine screening policies in emer-
gency rooms has rarely been attempted in Germany and
will face considerable financial and logistical challenges.
Primary medical care is another setting that provides
opportunities for HCV-testing. This should be enhanced
for example through increasing awareness among physi-
cians and decreasing barriers e.g. through on-site testing
[18] or opt-out testing [19].
Low threshold drug services are important needle/syr-
inge exchange sites in Germany. They were frequented
by a high proportion of NI making them ideal places for
integrated testing. Unfortunately—and in contrast to
many other countries—in Germany, it is required that a
physician is on-site when HCV-testing is performed and
test results are given, which currently greatly limits feasi-
bility for testing in this setting. Training non-physician
providers to perform testing could increase feasibility
and uptake of HCV-testing and has been successfully
employed in other countries e.g. Scotland [20].
Other alternatives might be targeted distribution of
HCV self-test kits in low threshold drug services or
through vending machines, which would require legal
changes (HIV self-tests are currently freely available, but
HCV self-tests are not).
In the UK and in the USA, distribution of HIV self-
tests through vending machines at venues frequented by
gay men is being explored [21, 22]. To our knowledge,
this has never been tested for PWID, but since they are
used to vending machines for clean injection equipment,
it might be worth studying acceptance and use of pro-
viding access to HCV self-test kits through vending ma-
chines for PWID.
Pharmacies, as the other important supplier of sterile in-
jection equipment, currently play no role in other aspects
of the HCV care cascade in Germany. However, studies
from other countries suggest that they can be valuable
and successfully offer and enhance HCV-testing, linkage
to specialist care and even provide treatment [23–25].
Pharmacies could also be a source to access (free or subsi-
dised) HCV self-tests.
In our study, if available, syringe vending machines
were an important source for syringes and needles for
NI and were more frequently used by NI with shorter
duration of IDU.
This finding is in line with a previous study among
PWID in Berlin, that users of vending machines often
reported a shorter duration of IDU [26]. The authors
suggest that in the first time after initiation of IDU,
PWID might prefer to obtain their injection equipment
anonymously and may not (yet) be willing to visit other
Table 2 HCV-status, awareness, injection behaviour and access to addiction and medical care of new injectors by self-reported HCV-
testing experience prior to study (Continued)
Reported previous HCV-test (N = 153) Reported no previous HCV-test (N= 56) p
n %i n %i
Injection of methamphetaminesh 5 3.3 11 19.6 < 0.001
aBorn in Germany, mother and/or father born abroad
bBorn outside of Germany
cDefined as reporting living on the streets or in homeless shelters as main residence in the last 12months
dNot asked in Berlin, Essen
eSubstance consumed in the last 30 days and most common mode of consumption injection
eExist in Berlin, Essen, Cologne, Munich
fNot asked in Berlin, Essen, Leipzig
gSubstance consumed in the last 30 days and most common mode of consumption injection
hConsumption of methamphethamine was concentrated in Leipzig (East Germany) and to a lower extent in Munich (South Germany), while it played almost no
role in other study cities
iof responding participants
*p < 0.05
**p < 0.01
***p < 0.001
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drug services [26]. French data showed that vending ma-
chines were used by younger PWID, that were hardly
reached by other syringe programs [27]. Although they
do not facilitate HCV-testing or support NI in other as-
pects of harm reduction, syringe vending machines are a
valuable prevention measure, supplying sterile injection
equipment around the clock.
Almost 25% of NI that reported no previous HCV testing
had been in prison in the last 12months. PWID are over-
represented in prison populations worldwide, making
prisons suitable settings to deliver HCV prevention (and
care) interventions, including HCV-screening [28–30]. Ac-
cording to a review and a cross-sectional survey, measures
in European prisons are currently inadequate and need to
be scaled up [28, 29]. Universal opt-out HCV-screening in
prisons was found to be cost-effective and able to reduce
HCV transmission in an American study [31]. It has been
introduced in California [32] and has increased screening
uptake among prisoners in England [33].
Homelessness was reported by more than 20% of NI
in our study, comparable to the findings of a very similar
study of NI in Catalonia [10]. Unstable housing has been
found to be a risk factor for HCV infection among
PWID in Vancouver [34], and in Puerto Rico, homeless
PWID were significantly more likely to engage in high-
risk injection behaviour than other PWID [35]. There is
experience e.g. from London on how to reach the home-
less population with HCV services [36, 37] .
Conclusion
It is important that HCV-counselling and testing are not
restricted to medical addiction care, especially for NI. It
should be offered in all facilities or settings where NI
can be reached, including hospitals and primary medical
care, prisons and needle/syringe exchange sites, espe-
cially low-threshold drug services. To reach HCV elim-
ination goals and increase feasibility of HCV-testing in
the setting of low-threshold drug services which are fre-
quented by the majority of NI, consideration should be
given to allow trained non-physician providers to con-
duct HCV testing. Feasibility and acceptability of HCV
self-testing for PWID should be explored.
Limitations
The number of NI was small, so results have to be inter-
preted with caution. HCV-testing experience was self-
reported; it is therefore possible that participants have
been tested without their knowledge or that recall was
incorrect. If participants reported no previous HCV-
testing, reasons for this were not explored, so we cannot
rule out that a test was offered but not accepted. Most
seeds (initial study participants selected as recruiters/
who “initiate sampling chains”) were recruited through
low-threshold drug services which were also used as
study sites; this might have led to overestimation of con-
tact with low-threshold drug services in some of the cit-
ies. As this was a cross-sectional study, we cannot draw
conclusions on causality. There were regional differences
in the size and characteristics of the population and as
the population of NI is unknown, our sample might not
be representative of all new injectors in Germany.
Nevertheless the DRUCK study is the first large bio-
behavioural study of current PWID in Germany and
provides valuable information about characteristics of
this group.
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